Journal article
Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: A randomised, double-blind, placebo-controlled trial
JE Bines, M Danchin, P Jackson, A Handley, E Watts, KJ Lee, A West, D Cowley, MY Chen, GL Barnes, F Justice, JP Buttery, JB Carlin, RF Bishop, B Taylor, CD Kirkwood, K Boniface, N Bogdanovic-Sakran, D Pavlic, W Siero Show all
Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2015
Abstract
Background: Despite the success of rotavirus vaccines, suboptimal vaccine efficacy in regions with a high burden of disease continues to present a challenge to worldwide implementation. A birth dose strategy with a vaccine developed from an asymptomatic neonatal rotavirus strain has the potential to address this challenge and provide protection from severe rotavirus disease from birth. Methods: This phase 2a randomised, double-blind, three-arm, placebo-controlled safety and immunogenicity trial was undertaken at a single centre in New Zealand between Jan 13, 2012, and April 17, 2014. Healthy, full-term (≥36 weeks gestation) babies, who weighed at least 2500 g, and were 0-5 days old at the ti..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Australian National Health and Medical Research Council, the New Zealand Health Research Council, and the Murdoch Childrens Research Institute.